CymaBay

CBAY NASDAQ
6.50
+0.28
+4.50%
After Hours: 6.50 0 0.00% 16:25 07/22 EDT
Open
6.21
Prev Close
6.22
High
6.52
Low
6.13
Volume
595.37K
Avg Vol (3M)
1.34M
52 Week High
14.00
52 Week Low
4.820
% Turnover
0.87%
Market Cap
446.52M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers CymaBay CBAY stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company's product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.
MORE >

Recently

Name
Price
%Change